Table 3.
Treatment-related side effects per dose level
| Toxicity | Events | Dose level
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 (n = 3)
|
2 (n = 6)
|
2a (n = 2)
|
||||||||
| G1 | G2 | G3 | G1 | G2 | G3 | G1 | G2 | G3 | ||
| Neutropenia | 1 | 1 | ||||||||
| Anemia | 6 | 2 | 1 | 2 | 1 | |||||
| Fever | 1 | 1 | ||||||||
| Fatigue | 8 | 2 | 4 | 1 | 1 | |||||
| Pain musculoskeletal | 5 | 2 | 2 | 1 | ||||||
| Neuropathy sensory | 2 | 2 | ||||||||
| Nausea | 11 | 3 | 1 | 5 | 2 | |||||
| Vomiting | 6 | 2 | 1 | 2 | 1 | |||||
| Diarrhea | 6 | 1 | 2 | 1* | 1 | 1 | ||||
| Dyspepsia | 7 | 2 | 2 | 1 | 1 | 1 | ||||
| Anorexia | 5 | 1 | 3 | 1 | ||||||
| Taste alteration | 5 | 1 | 1 | 1 | 1 | 1 | ||||
| Flatulence | 2 | 2 | ||||||||
| ALT elevation | 1 | 1* | ||||||||
| AST elevation | 1 | 1 | ||||||||
| Dry skin | 2 | 1 | 1 | |||||||
| Rash | 6 | 3 | 1 | 1 | 1 | |||||
| Nasal reactions | 2 | 1 | 1 | |||||||
| Epiphora | 5 | 1 | 4 | |||||||
| Dry eye | 6 | 1 | 1 | 1 | 2 | 1 | ||||
| Alopecia | 7 | 2 | 1 | 4 | ||||||
| Nail changes | 2 | 1 | 1 | |||||||
| Mucositis | 1 | 1 | ||||||||
| Edema limb | 3 | 1 | 2 | |||||||
| Facial edema | 5 | 2 | 3 | |||||||
| Hot flashes | 1 | 1 | ||||||||
| Flushing | 2 | 1 | 1 | |||||||
| Dehydration | 1 | 1 | ||||||||
| Hypokalemia | 1 | 1 | ||||||||
Note: Number of worst grade adverse events possibly, probably, or definitely attributed to docetaxel or imatinib during study drug administration. Toxicities are graded per the NCI CTCAE version 3 criteria. G1 Grade 1, G2 Grade 2, G3 Grade 3. Dose-limiting toxicities are indicated by *